Atherosclerosis Market Forecasts to 2034 - Global Analysis By Disease Type, Diagnosis Modality, Treatment Modality, Route of Administration, Distribution Channel, End User and By Geography

According to Stratistics MRC, the Global Atherosclerosis Market is accounted for $32.5 billion in 2026 and is expected to reach $55.2 billion by 2034 growing at a CAGR of 6.8% during the forecast period. The Atherosclerosis Market focuses on diagnostic technologies, pharmacological treatments, endovascular procedures, and surgical interventions for managing atherosclerosis, a chronic cardiovascular condition characterized by the accumulation of lipid-rich plaques within arterial walls. Increasing prevalence of cardiovascular diseases, aging populations, and rising incidence of diabetes, hypertension, and dyslipidemia are supporting market expansion. Advancements in lipid-lowering therapies, vascular imaging, minimally invasive interventions, and targeted cardiovascular treatments are improving disease management. Growing healthcare expenditure, expanding preventive screening programs, and increasing investment in innovative cardiovascular technologies are further encouraging market development worldwide.

Market Dynamics:

Driver:

Increasing prevalence of cardiovascular diseases and associated metabolic disorders

The increasing prevalence of cardiovascular diseases and metabolic disorders is a major driver of the atherosclerosis market. Rising rates of diabetes, obesity, hypertension, and elevated cholesterol contribute to the development and progression of arterial plaque formation. Aging populations and sedentary lifestyles are further increasing cardiovascular risk across many regions. Greater awareness of preventive healthcare, expanding cholesterol screening programs, and improved access to cardiovascular diagnostics are encouraging earlier disease detection. Additionally, growing adoption of lipid-lowering medications and minimally invasive vascular interventions is supporting treatment demand and long-term market expansion.

Restraint:

High treatment costs and limited access to advanced cardiovascular diagnostics

High treatment costs and unequal access to advanced cardiovascular services are significant restraints on market growth. Diagnostic procedures such as computed tomography angiography, magnetic resonance angiography, and intravascular imaging can involve substantial equipment and operational expenses. Advanced lipid-lowering therapies, endovascular interventions, and surgical procedures may also impose considerable financial burdens on patients and healthcare systems. Limited reimbursement coverage and inadequate specialist availability in developing regions can restrict treatment adoption. Additionally, complex treatment regimens, medication-related adverse effects, and poor patient adherence may reduce the effectiveness of long-term disease management.

Opportunity:

Development of innovative lipid-lowering therapies and precision cardiovascular medicine

Advancements in lipid-lowering therapies and precision cardiovascular medicine are creating significant opportunities for market participants. Pharmaceutical companies are developing treatments targeting PCSK9, lipoprotein(a), and other pathways associated with atherosclerotic cardiovascular disease. RNA-based therapies, gene-editing approaches, and novel cholesterol-lowering medications may expand treatment options for patients with persistent cardiovascular risk. Improvements in vascular imaging, artificial intelligence-assisted diagnostics, and personalized risk assessment are supporting earlier intervention. Growing investment in cardiovascular research and expanding access to preventive treatment programs may further accelerate market development.

Threat:

Regulatory complexities and increasing competition from generic cardiovascular medications

Stringent regulatory requirements and growing competition from generic medications present significant threats to the atherosclerosis market. Developers of innovative cardiovascular therapies must demonstrate clinical safety, effectiveness, and meaningful cardiovascular outcomes through extensive clinical studies. Patent expirations and the widespread availability of low-cost generic statins can create pricing pressure for branded pharmaceutical manufacturers. Potential adverse effects, treatment discontinuation, and uncertainty surrounding reimbursement policies may also influence market adoption. Additionally, healthcare budget constraints, supply chain disruptions, and variations in clinical guidelines can create challenges for pharmaceutical and medical technology companies.

Covid-19 Impact:

The COVID-19 pandemic affected the atherosclerosis market through disruptions in routine cardiovascular screening, diagnostic imaging, and elective vascular procedures. Healthcare systems prioritized emergency services, resulting in delayed consultations and interventions for some patients with chronic cardiovascular conditions. Interruptions in preventive care and lipid monitoring complicated long-term risk management. However, telemedicine consultations, remote patient monitoring, and electronic prescription services gained importance during the pandemic. Subsequent recovery in cardiovascular healthcare services, renewed emphasis on preventive medicine, and continued adoption of digital health technologies supported market stabilization and further development.

The coronary artery atherosclerosis segment is expected to be the largest during the forecast period

The coronary artery atherosclerosis segment is expected to account for the largest market share during the forecast period due to the substantial burden of coronary artery disease and its associated treatment requirements. Plaque accumulation within coronary arteries can reduce myocardial blood supply and increase the risk of angina and acute coronary events. Management frequently involves lipid-lowering medications, antiplatelet therapies, diagnostic imaging, and revascularization procedures when clinically indicated. Increasing cardiovascular screening, improved diagnostic capabilities, and expanding availability of minimally invasive coronary interventions are supporting segment development. Continued investment in cardiovascular therapeutics further strengthens its market position.

The endovascular procedures segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the endovascular procedures segment is predicted to witness the highest growth rate due to increasing adoption of minimally invasive techniques for managing selected atherosclerotic vascular conditions. Angioplasty, stent placement, and other catheter-based interventions can restore blood flow in appropriately selected patients while reducing procedural invasiveness compared with certain open surgical approaches. Advancements in drug-eluting stents, vascular imaging, and catheter technologies are improving procedural capabilities. Growing availability of specialized cardiovascular centers and increasing demand for shorter hospital stays are supporting adoption. Continued technological innovation may further accelerate segment growth.

Region with largest share:

During the forecast period, North America is expected to hold the largest market share, supported by advanced cardiovascular healthcare infrastructure, substantial healthcare expenditure, and widespread availability of diagnostic and therapeutic technologies. The United States represents a major market due to the significant burden of atherosclerotic cardiovascular disease, established specialist treatment networks, and strong pharmaceutical research activity. Increasing adoption of advanced lipid-lowering medications, vascular imaging, and minimally invasive interventions is supporting market development. Continued investment in preventive cardiovascular care and innovative treatment technologies further strengthens regional performance.

Region with highest CAGR:

Over the forecast period, Asia Pacific is anticipated to exhibit the highest CAGR due to increasing cardiovascular disease prevalence, rapidly aging populations, and expanding healthcare infrastructure. China, India, Japan, South Korea, and Australia represent important markets for atherosclerosis diagnosis and treatment. Rising incidence of diabetes, hypertension, and dyslipidemia is increasing demand for preventive cardiovascular services. Growing healthcare expenditure, improving access to diagnostic imaging, and expanding adoption of advanced cardiovascular therapies are supporting regional development. Government initiatives promoting early screening and increasing investment in specialized cardiac facilities may further encourage market growth.

Key players in the market

Some of the key players in the Atherosclerosis Market include AstraZeneca, Bayer AG, Merck & Co. Inc., Novartis AG, Sanofi, Pfizer Inc., Amgen, Regeneron Pharmaceuticals, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, AbbVie Inc., Boehringer Ingelheim, Daiichi Sankyo Company, Limited, Novo Nordisk A/S, Ionis Pharmaceuticals, Verve Therapeutics, Inc., and NewAmsterdam Pharma.

Key Developments:

In September 2026, Ionis Pharmaceuticals announced that its partner Novartis had reported topline Phase III results from the Lp(a)HORIZON study evaluating pelacarsen in patients with elevated lipoprotein(a) and established cardiovascular disease. The development represents an important milestone in investigating RNA-targeted approaches to cardiovascular risk reduction.

In August 2026, NewAmsterdam Pharma reported a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use recommending marketing authorization for obicetrapib and its fixed-dose combination with ezetimibe. The investigational treatments target elevated LDL cholesterol in patients requiring additional lipid management.

In July 2026, Amgen announced that the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion supporting broader use of Repatha (evolocumab) in adults with established or high risk for atherosclerotic cardiovascular disease. The recommendation was supported by Phase III VESALIUS-CV trial findings demonstrating cardiovascular event reduction in high-risk patients.

Disease Types Covered:

• Coronary Artery Atherosclerosis
• Carotid Artery Atherosclerosis
• Peripheral Artery Atherosclerosis
• Renal Artery Atherosclerosis
• Aortic Atherosclerosis

Diagnosis Modalities Covered:

• Laboratory Testing
• Ultrasound Imaging
• Computed Tomography Angiography (CTA)
• Magnetic Resonance Angiography (MRA)
• Catheter-Based Angiography
• Intravascular Imaging

Treatment Modalities Covered:

• Pharmacological Therapy
• Endovascular Procedures
• Surgical Procedures

Routes of Administration Covered:

• Oral
• Parenteral

Distribution Channels Covered:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

End Users Covered:

• Hospitals
• Specialty Cardiovascular Centers
• Specialty Clinics
• Ambulatory Surgical Centers

Regions Covered:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Netherlands
  • Belgium
  • Sweden
  • Switzerland
  • Poland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Malaysia
  • Singapore
  • Vietnam
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Colombia
  • Chile
  • Peru
  • Rest of South America
• Rest of the World (RoW)
  • Middle East
    • Saudi Arabia
    • United Arab Emirates
    • Qatar
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Egypt
    • Morocco
    • Rest of Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances